(Q83198490)
Statements
The application of mechanism-based PK/PD modeling in pharmacodynamic-based dose selection of muM17, a surrogate monoclonal antibody for efalizumab (English)
Benjamin Wu
Amita Joshi
Song Ren
scientific article published on 01 June 2006